Inosinic acid
|
Basic information |
| Metabolite name | Inosinic acid |
 | HMDB0000175 |
 |
C00130 |
 |
8582 |
| Synonyms | Inosine 5'-monophosphate; |
| No. of studies | 11 |
|
Basic information |
| Metabolite name | Inosinic acid |
| HMDB0000175 |
|
C00130 |
|
8582 |
| Synonyms | Inosine 5'-monophosphate; |
| No. of studies | 11 |
|
Relationship between Inosinic acid and depression (count: 11) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M582 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M582 | Type3 | control + fluoxetine group vs. control group | Hippocampus | C57BL/6N mouse | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Up |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M940 | Type2 | CUMS + Chaihu group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M940 | Type2 | CUMS + Chaihu-Baishao herb pair group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |